Search clinical trials for: Hepatitis C Virus Pegylated Interferon Ribavirin Older

Total 494192 results

Kaohsiung Medical University Chung-Ho Memorial...

Completed

Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
Kyushu University

Unknown

PEG-IFN Plus Ribavirin Combination Therapy for Older Patients

Hepatitis C Virus

Japan
Melbourne Health
Hoffmann-La Roche; Monash University; The University of New South Wales; St Vincent... and other collaborators

Completed

Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy

Chronic Hepatitis C

Australia
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

Hepatitis C

United States, Belgium
Tanta University

Completed

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Hepatitis C

Egypt
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV (DIMENSION)

Chronic Hepatitis C Infection

France, Germany, United States, Spain, Canada, Argentina, Mexico, Belgium, Italy, Russian Federation, United Kingdom, Poland
AbbVie

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (DORA)

Hepatitis C Virus (HCV)

United States, Belgium, Canada, Germany, Japan, Puerto Rico, Russian Federation, Spain, United Kingdom
Queen Mary University of London
Nottingham University Hospitals NHS Trust; Barts & The London NHS Trust; Janssen-Cilag... and other collaborators

Completed

Telaprevir in Genotype 3 HCV (TIG3)

Hepatitis C

United Kingdom
Cellectar Biosciences, Inc.

Completed

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy (NOV-205)

Hepatitis C

United States
National Institute of Allergy and Infectious Diseases...

Completed

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

HIV Infections | Hepatitis C | Liver Disease

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

HIV Infection | Hepatitis C Infection

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

HIV Infections | Hepatitis C

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

HIV Infections | Hepatitis C

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

HIV Infections | Hepatitis C

United States
National Institutes of Health Clinical Center (CC)

Completed

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

HIV Infection | Hepatitis C Infection

United States
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
Johns Hopkins Bloomberg School of Public Health
National Institute on Drug Abuse (NIDA); YR Gaitonde Centre for AIDS Research...

Completed

Directly Observed Therapy for HCV in Chennai, India (C-DOT)

Hepatitis C, Chronic

India
Merck Sharp & Dohme LLC

Completed

A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

Hepatitis C Infection
Merck Sharp & Dohme LLC

Completed

A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Chronic Hepatitis C (CHC)
M.D. Anderson Cancer Center
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Infection

United States
Merck Sharp & Dohme LLC

Completed

Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED) (Pegade)

Hepatitis C, Chronic
Bristol-Myers Squibb

Completed

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia (MAGNITUDE)

Hepatitis C Virus

Australia, France, United States, Spain, Italy, Netherlands, Romania, Russian Federation
University of California, San Francisco
California HIV/AIDS Research Program

Completed

Treatment of Acute Hepatitis C Virus in HIV Co-Infection

HIV Infections | Hepatitis C | Human Immunodeficiency Virus

United States
Beni-Suef University

Completed

Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4 (HCV)

Hepatitis C Virus Infection
Bausch Health Americas, Inc.

Completed

Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy

Chronic Hepatitis C
Kirby Institute
Merck Sharp & Dohme LLC

Completed

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 (ACTIVATE)

Hepatitis C, Chronic

Australia, Canada, United Kingdom, Belgium, Germany, Norway, Switzerland
OPKO Health, Inc.

Completed

Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin

Hepatitis, Viral, Human | Chronic Hepatitis C

Canada
Institut de Recherche pour le Developpement
Ministry of Health, Thailand

Completed

HCV-HIV Co-infected Patient Cohort in Thailand

HIV | Hepatitis C Infection

Thailand
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment (EXPEDITION-5)

Hepatitis C Virus (HCV)

United States, Canada, Germany, Greece, Italy, Korea, Republic of, Poland, Puerto Rico, Spain, Sweden
Idera Pharmaceuticals, Inc.

Completed

Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients

Hepatitis C

United States, Puerto Rico
R-Pharm

Completed

Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study) (PIONEER)

Hepatitis C

Russian Federation
National Institute of Diabetes and Digestive and...
Roche Pharma AG

Completed

PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C

Chronic Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

Hepatitis C
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C Virus Infection

United States, Puerto Rico
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Chronic Hepatitis C | Hepatitis C Virus (HCV) Infection

United States, Puerto Rico
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study

Chronic Hepatitis C
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults (MALACHITE II)

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before (MALACHITE 1)

Chronic Hepatitis C Infection
Parc de Salut Mar

Completed

Impact of Antiviral Therapy on Gastroesophageal Varices.

Cirrhosis | Chronic Hepatitis C
Eisai Inc.

Completed

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Thrombocytopenia

United States
GlaxoSmithKline
PPD

Completed

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C, Chronic

Puerto Rico, United States
Hoffmann-La Roche
Santaris Pharma A/S

Completed

Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin

Chronic Hepatitis C

Puerto Rico
Hoffmann-La Roche

Completed

APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin

Hepatitis C, Chronic

Canada
Hoffmann-La Roche

Completed

A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C

Hepatitis C, Chronic

Georgia
AbbVie

Completed

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a

3

Subscribe